UPB (Upstream Bio) FCF Margin % : 0.00% (As of Dec. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Upstream Bio FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Upstream Bio's Free Cash Flow for the three months ended in Dec. 2024 was $0.00 Mil. Upstream Bio's Revenue for the three months ended in Dec. 2024 was $0.61 Mil. Therefore, Upstream Bio's FCF Margin % for the quarter that ended in Dec. 2024 was 0.00%.

As of today, Upstream Bio's current FCF Yield % is -18.24%.

The historical rank and industry rank for Upstream Bio's FCF Margin % or its related term are showing as below:

UPB' s FCF Margin % Range Over the Past 10 Years
Min: -4892.05 Med: -1599.58 Max: -1576.16
Current: -4892.05

During the past 3 years, the highest FCF Margin % of Upstream Bio was -1576.16%. The lowest was -4892.05%. And the median was -1599.58%.

UPB's FCF Margin % is ranked worse than
88.9% of 1009 companies
in the Biotechnology industry
Industry Median: -128.43 vs UPB: -4892.05

Upstream Bio FCF Margin % Historical Data

The historical data trend for Upstream Bio's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Upstream Bio FCF Margin % Chart

Upstream Bio Annual Data

Trend

Dec22

Dec23

Dec24

FCF Margin %

-1,576.16

-1,599.58

-2,518.27

Upstream Bio Quarterly Data
	Dec22	Jun23	Sep23	Dec23	Jun24	Sep24	Dec24
FCF Margin %	Get a 7-Day Free Trial			-	-	-	-	-

Competitive Comparison of Upstream Bio's FCF Margin %

For the Biotechnology subindustry, Upstream Bio's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Upstream Bio's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Upstream Bio's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Upstream Bio's FCF Margin % falls into.

Save Embed

;

Save Embed

;

Upstream Bio FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Upstream Bio's FCF Margin for the fiscal year that ended in Dec. 2024 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2024 )	/	Revenue (A: Dec. 2024 )
	=	-59.683	/	2.37
	=	-2,518.27 %

Upstream Bio's FCF Margin for the quarter that ended in Dec. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2024 )	/	Revenue (Q: Dec. 2024 )
	=	0	/	0.613
	=	0.00 %

Upstream Bio FCF Margin % Related Terms

Thank you for viewing the detailed overview of Upstream Bio's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Upstream Bio Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Upstream Bio Inc (NAS:UPB) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

890 Winter Street, Suite 200, Waltham, MA, USA, 02451

Website

https://www.upstreambio.com

Upstream Bio Inc is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. It is developing verekitug, the known antagonist currently in clinical development that targets the receptor for Thymic Stromal Lymphopoietin (TSLP), a cytokine that is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune-mediated diseases.